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Abstract
Background and Aims: Recent studies have shown that dietary red palm oil (RPO) supplementation improves 
functional recovery following ischaemia/reperfusion in isolated hearts. The main aim of this study was to investigate 
the effects of dietary RPO supplementation on myocardial infarct size after ischaemia/reperfusion injury. The effects of 
dietary RPO supplementation on matrix metalloproteinase-2 (MMP2) activation and PKB/Akt phosphorylation were 
also investigated.
Materials and methods: Male Wistar rats were divided into three groups and fed a standard rat chow diet (SRC), a SRC 
supplemented with RPO, or a SRC supplemented with sunflower oil (SFO), for a five week period, respectively. After the 
feeding period, hearts were excised and perfused on a Langendorff perfusion apparatus. Hearts were subjected to 
thirty minutes of normothermic global ischaemia and two hours of reperfusion. Infarct size was determined by 
triphenyltetrazolium chloride staining. Coronary effluent was collected for the first ten minutes of reperfusion in order 
to measure MMP2 activity by gelatin zymography.
Results: Dietary RPO-supplementation decreased myocardial infarct size significantly when compared to the SRC-
group and the SFO-supplemented group (9.1 ± 1.0% versus 30.2 ± 3.9% and 27.1 ± 2.4% respectively). Both dietary 
RPO- and SFO-supplementation were able to decrease MMP2 activity when compared to the SRC fed group. PKB/Akt 
phosphorylation (Thr 308) was found to be significantly higher in the dietary RPO supplemented group when 
compared to the SFO supplemented group at 10 minutes into reperfusion. There was, however, no significant changes 
observed in ERK phosphorylation.
Conclusions: Dietary RPO-supplementation was found to be more effective than SFO-supplementation in reducing 
myocardial infarct size after ischaemia/reperfusion injury. Both dietary RPO and SFO were able to reduce MMP2 activity, 
which suggests that MMP2 activity does not play a major role in protection offered by RPO. PKB/Akt phosphorylation 
may, however, be involved in RPO mediated protection.
Background
Little is known about the effects of dietary edible oil sup-
plementation on myocardial infarct size. Previous studies
demonstrated that dietary RPO supplementation offers
protection against ischaemia/reperfusion injury by
improved aortic output recovery [1-4]. Engelbrecht and
co-workers (2006) found that 6 weeks of dietary RPO
supplementation was associated with increased PKB/Akt
and p38 phosphorylation and decreased phosphorylation
of JNK, when compared to standard rat chow fed con-
trols. This suggests that RPO may inhibit apoptosis
through MAPK and PKB/Akt signaling pathways. RPO-
supplementation was shown to increase cGMP levels
early in ischaemia [3,4]. NO levels in myocytes of RPO
supplemented rats was increased after hypoxic condi-
tions when compared to standard rat chow fed controls.
This suggests that RPO-supplementation upregulate NO-
cGMP signaling. In subsequent studies by Van Rooyen
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and co-workers (2008) summarized these results in a
review and proposed several possible protective pathways
[5]. Engelbrecht and co-workers (2009) also found that
the inhibition of the PI3K pathway by pharmaceutical
drug, wortmanin (a specific PI3K inhibitor) led to a loss
of the improved functional recovery after ischaemia in
RPO supplemented groups [6]. However, the inhibition of
PI3K by wortmanin could only reduce functional recov-
ery in RPO supplemented groups partially, suggesting
that there may be more than one pathway of RPO-medi-
ated protection involved. These studies have shown that
dietary RPO supplementation is able to increase reperfu-
sion function. However, there is some evidence that con-
tractile dysfunction in non-infarcted myocardial tissue
may play a role in cardiac function early after ischaemia
[7]. This necessitates the measurement of myocardial
infarct size to determine the efficacy of dietary RPO-sup-
plementation in offering protection against ischaemia/
reperfusion injury.
Myocardial infarction is one of the leading causes of
mortality globally [8-10]. Research has shown that a
decrease in infarct size leads to improved ventricular
function [11-13]. Furthermore, function was better in
hearts with small infarcts a year after the myocardial inci-
dent, when compared to functional measurements at ini-
tial discharge from hospital [11]. There is however,
uncertainty as to the reason why ischaemic myocytes are
killed and this complicates the search for agents that may
reduce myocardial infarct size.
Overproduction of reactive oxygen species (ROS) may
be considered as one of the major causes of tissue death
in myocardial infarction [14-18]. As RPO contains several
antioxidant micronutrients, we hypothesize that the anti-
oxidative action of RPO may indeed contribute to the
protection offered by RPO against ischaemia/reperfusion
injury.
Matrix metalloproteinases (MMPs) are calcium and
zinc dependant, endopeptidases which facilitate cell
migration and tissue remodelling [19]. Recently it was
found that MMP2 plays a role in ischaemia/reperfusion
injury to the heart [20]. Activation of MMP2 during an
ischaemic insult is associated with poor recovery and
larger infarct size of the heart [20-24]. However, inhibi-
tion of MMP2 may lead to improved myocardial recovery
after ischaemia/reperfusion injury [25-29]. MMP2 may
be activated by oxidative/nitrosative stress, which is asso-
ciated with myocardial infarction [30]. Activation of
MMP2 by ROS is achieved through redox modification of
the regulatory region of the pro-MMP molecule [31,32].
This redox modification leads to the demonstration of
activity in the 72 kDa isoform of MMP-2, which is nor-
mally a pro-MMP isoform. Activated MMP2 damages
cardiomyocytes during reperfusion by cleaving the con-
tractile protein regulatory element, troponin I or other
structural proteins [33-38].
Our aims for this study were: 1) to measure infarct size
in dietary RPO-supplemented rat hearts which have been
exposed to ischaemia/reperfusion injury and 2) to deter-
mine the effects of dietary RPO-supplementation on
myocardial MMP2 activation and PKB/Akt phosphoryla-
tion.
Materials and methods
All rats received humane animal care in accordance with
the Guide for the Care and Use of Laboratory Animals,
published by the U.S. National Institutes of Health (NIH
publication 8523, revised 1985).
Experimental design
Male Wistar rats were randomly divided into three
groups and fed a standard rat chow diet (SRC), a SRC
supplemented with RPO (200([0-9]+) μl/day), or a SRC
supplemented with sunflower oil (SFO, 200([0-9]+) μl/
day), for a five week period, respectively (Figure 1). The
rats were individually housed to ensure that each animal
received equal amounts of supplements, which were pre-
pared on a daily basis in order to prevent spoiling. Sup-
plements were added to rat chow that was ground finely
with a pestle and mortar. All rats were allowed ad libitum
access to food and water. For a brief description of sup-
plements see Table 1.
After the feeding period, rat hearts were perfused for
infarct size determination and analysis of Akt and ERK
phosphorylation. Coronary effluent was collected during
reperfusion for analysis of MMP2 and LDH activity.
Serum obtained from the thoracic cavity of rats after
removal of the heart was used for serum cholesterol and
triglyceride determinations (Figure 1).
Isolated heart perfusion
After the feeding period, rats were anaesthetized using
diethyl ether. Hearts were rapidly excised, then mounted
on a Langendorff perfusion apparatus and were perfused
at 37°C at a constant pressure (75 mmHg) using a Krebs
Henseleit buffer gassed with a mixture of 5% carbon diox-
Table 1: A brief breakdown of the content of oils, used as 
supplements in the diets of this study
Sunflower oil Red palm oil
SFA (%) 12 51
MUFA (%) 26 38
PUFA (%) 62 11
Carotenoids (ppm) - 500
Vitamin E (ppm) ± 500 500-1100
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ide and 95% oxygen. After mounting, hearts were sub-
jected to 10 minutes of stabilization, followed by 30
minutes of normothermic global ischaemia and 120 min-
utes of reperfusion. At the end of the protocol ventricular
tissue was frozen at -20°C overnight. Hearts for biochem-
ical analysis were snap frozen after the 10 minute stabili-
zation period and also after 10 minutes reperfusion.
Infarct size determination
Frozen hearts were cut into 2 mm thick cross-sectional
slices. These slices were stained in 2, 3, 5-triphenyltetra-
zolium chloride (TTC) for 10 minutes at 37°C. After TTC
staining, the slices were transferred to a formalin solution
for ten minutes and then placed in phosphate buffer (pH
7.4). Heart slices were then placed between two sheets of
glass and scanned into a computer and analyzed using
infarct size planimetry software (InfarctSize™ 1.0, Phar-
mahungary Szeged, Hungary). Infarct size was repre-
sented as percentage of the area at risk.
LDH measurement
Lactate dehydrogenase (LDH) release from hearts was
measured in coronary effluent samples that were col-
lected for the first 5 min of reperfusion, using a LDH-P
kit (Diagnosticum Zrt., Budapest, Hungary). The kit
makes use of spectrophotometric measurement to deter-
mine the absorbance of substrate catalyzed by the
enzyme.
MMP2 zymography
Coronary effluent collected for the first 10 minutes of
reperfusion was concentrated by ultra filtration using
Amicon ultra filtration tubes. The concentrated coronary
flow was then subjected to gelatin zymography. Gelati-
nolytic activities of MMPs were examined as previously
described [39]. Briefly, polyacrylamide gels were copoly-
merized with gelatin, and a 10 μg protein was separated
by electrophoresis in each lane. Following electrophore-
sis, gels were washed with 2.5% Triton X-100 and incu-
bated for 20 hours at 37°C in incubation buffer. Gels were
Table 2: Weight of rats, and rat hearts after a five week supplementation period. 
SRC Sunflower oil Red palm oil
Animal mass (gram) 422 ± 8 403 ± 7 381 ± 7 *#
Heart mass (gram) 1.57 ± 0.06 1.44 ± 0.04 1.40 ± 0.03 *
*P < 0.05 vs Ctrl, #P < 0.05 vs SFO
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then stained with 0.05% Coomassie Brilliant Blue in a
mixture of methanol/acetic acid/water and destained in
aqueous 4% methanol/8% acetic acid. Zymograms were
digitally scanned, and band intensities were quantified
using Quantity One software (Bio-Rad, Hercules, CA).
Western Blot
Heart tissue homogenized by adding homogenization
buffer and PMSF to the sample. For phosphoprotein
determination NaF and Na3VO4 were added to the sam-
ple after which samples were sonicated for 3 times 10 sec-
onds and then centrifuged at 15000 rpm for 15 minutes.
Protein concentration was determined by the bicin-
choninic acid method.
Samples were diluted with Laemmli sample buffer and
boiled, after which 40 μg of protein was separated by
SDS-PAGE electrophoresis. After electrophoresis the
proteins were transferred to PVDF membranes. Mem-
branes where routinely stained with Ponceau in order to
check for equal loading and sufficient transfer. Non spe-
cific binding was blocked by overnight incubation in 5%
fat free milk in TBST. Membranes were then incubated
with primary antibodies that recognize Erk p42/44
(Thr202/Thr204) and PKB (Thr308). Membranes were sub-
sequently washed and incubated with secondary anti-
body. After thorough washing with TBST, membranes
were covered with ECL and exposed to autoradiography
films which were densitometrically analyzed.
Serum Cholesterol and Triglyceride measurement
Serum chol and TG were measured using a test kit sup-
plied by Diagnosticum Zrt. (Budapest, Hungary) as
described previously [40].
Statistical Methods
All values are presented as mean plus or minus standard
error of the mean. Significance between groups was
determined with one way ANOVA with Tukey Kramer
post hoc test. P was considered significant if it was less
than 0.05.
Results
Perfusion data and animal mass
The weight of rats from the RPO supplemented group
was significantly less than that of the control groups after
the feeding period (381 ± 7 g versus 422 ± 8 g for the SRC
and 403 ± 7 g for the SFO supplemented group). As ani-
mals were randomly divided into groups before the feed-
ing period this is an indication that rats supplemented
with RPO gained less weight in this time period (Table 2).
The weight of hearts isolated from the SRC group was
significantly increased when compared to those of the
RPO-supplemented group (1.57 ± 0.06g versus 1.40 ±
0.03g). However, hearts from the SFO-supplemented
group showed no difference when compared to the other
two groups (1.44 ± 0.04g) (Table 2).
There were no significant differences between the
groups with respect to heart rate and coronary flow
before or after ischaemia. Coronary flow was significantly
decreased after ischaemia in all groups when compared
to pre-ischaemic values (Table 3).
Infarct size and lactate dehydrogenase (LDH)
Infarct size was significantly reduced in the RPO-supple-
mented group when compared to the SRC and the SFO-
supplemented groups (9.1 ± 1.0 % versus 30.2 ± 3.9 % for
the SRC group and 27.1 ± 2.4 % for the SFO group,
respectively). However, dietary SFO-supplementation did
not reduce infarct size associated with ischaemia/reper-
fusion injury when compared to the SRC fed control rats
(Figure 2).
LDH levels in the reperfusion coronary effluent of the
RPO supplemented group was significantly decreased
Figure 2 Infarct size expressed as percentage of the area at risk of 
hearts that was subjected to 30 minutes global ischaemia and 

















Table 3: Functional parameters of hearts before and after ischaemia.
Coronary effluent before 
ischaemia (ml/10 min)
Coronary effluent after 
ischaemia (ml/10 min)
Heart rate before 
ischaemia (BPM)
Heart rate after 
ischaemia (BPM)
SRC 151 ± 11 91 ± 4* 347 ± 16 158 ± 32
SFO 195 ± 20 127 ± 16* 349 ± 12 251 ± 40
RPO 152 ± 12 100 ± 6* 344 ± 11 328 ± 40
*P < 0.05 versus the same group before ischaemia
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when compared to the SRC group (0.11 ± 0.01 U/ml/min
versus 0.07 ± 0.01 U/ml/min) (Figure 3).
Matrix Metalloproteinase 2 (MMP2)
MMP2 activity in both the 75 kDa and 72 kDa isoforms
were significantly decreased in the RPO and SFO-supple-
mented groups when compared to the SRC group (75
kDa: 1389 ± 124 arbitrary units and 1433 ± 103 arbitrary
units versus 1724 ± 69 arbitrary units; 72 kDa: 2635 ± 163
arbitrary units and 2597 ± 158 arbitrary units versus 3201
± 104 arbitrary units). There were no differences between
the RPO-supplemented and SFO-supplemented groups
for either the 75 kDa or the 72 kDa isoforms (Figure 4).
Western blot analysis
The RPO supplemented group showed significantly
increased Akt (thr) phosphorylation when compared to
the SFO supplemented group (Figure 5). The total Akt for
all groups were similar. There were no significant differ-
ences between any of the groups for total Erk 44 and 42 or
phosphorylated Erk 44 and 42 (Figure 5).
Serum lipid profile
The total serum cholesterol levels were similar in all the
groups. There was, however, a significant decrease in
serum triglyceride levels of both the SFO and RPO
groups when compared to the SRC group (0.75 ± 0.12
mmol/L and 0.71 ± 0.06 mmol/L versus 1.16 ± 0.12
mmol/L) (Figure 6).
Discussion
Our results demonstrate that dietary RPO-supplementa-
tion was able to reduce myocardial infarct size. Sunflower
oil supplementation however, was not able to reduce
myocardial infarct size when supplemented to the diet in
equal proportions as RPO, suggesting that the protection
offered by RPO is not a result of additional energy added
to the diet. This confirms results by Bester and co-work-
ers (2006) which showed that RPO supplementation
could offer protection against ischaemia/reperfusion
injury in diets of different fat content when compared to
isocaloric control groups. The reduction in infarct size in
the RPO supplemented group also correlates well with
functional results from previous studies where aortic out-
put recovery was measured during reperfusion [1,3,4].
Infarct size however, may be used as a longer term pre-
dictor of myocardial recovery [11,13]. The results of this
study together with the results of previous studies show
for the first time that dietary RPO is able to offer protec-
tion against ischaemia/reperfusion injury by improving
reperfusion function and reducing myocardial infarct
size. Our coronary flow results show that neither dietary
RPO supplementation, nor SFO supplementation was
able to improve post ischaemic vascular action. These
results are not in agreement with those of Esterhuyse and
co-workers (2006) or Bester and co-workers (2006),
where it was found that there was no singnificant differ-
ences between coronary flow before and after ischaemia
in any group. The results of these studies should however,
not be compared to the current study, as the model
employed in the current study makes use of a harsher
ischeamic temperature and time. Additionally the coro-
nary flow was reported at 10 minutes reperfusion in the
current study and at 25 minutes reperfusion in the above
mentioned studies. The difference in heart weight
between the RPO and SRC groups could be explained by
the difference in body weight. These results indicate that
Figure 3 Lactate dehydrogenase activity in coronary effluent col-
lected from isolated perfused hearts during the first five minutes 



















Figure 4 MMP2 75 and 72 kDa isoform activities in coronary efflu-
ent of isolated perfused rat hearts, collected during the first ten 
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dietary RPO-supplementation does not lead to increased
weight gain or cardiac hypertrophy.
Reduction of MMP2 activity is normally associated
with protection against ischaemia/reperfusion injury [21-
24]. Under normal physiological conditions the 75 kDa
and 72 kDa isoforms of MMP2 are inactive. These iso-
forms may however, display activity when partial cleavage
of the autoinhibitory propeptide domain takes place in
the presence of peroxynitrite and glutathione [31,32]. The
fact that both RPO-supplementation and SFO-supple-
mentation reduced the MMP2 activity suggests that both
of these oils may offer some protection against ischae-
mia/reperfusion injury when supplemented to the diet.
Alternatively, the reduction of MMP2 activity may not be
the only pathway involved in RPO-mediated protection.
The reduction of MMP2 (75 kDa and 72 kDa) activity
suggests that oxidative stress has been reduced by the
supplemented oils. However, dietary SFO-supplementa-
tion failed to decrease infarct size in this study. The
reduction in MMP2 activity in the SFO-supplemented
group was therefore not enough to offer protection
against ischaemia/reperfusion injury. This suggests that
MMP2 activity is not the only role player in the protec-
tion offered by RPO supplementation. Van Rooyen and
co-workers (2008) proposed that several mechanisms
synergistically offered RPO-mediated protection [5]. Our
results suggest that reduction in MMP2 activity may
together with other pathways such as 1) the NO-cGMP
pathway, 2) the PKB/Akt pathway and 3) the inhibition of
caspases, play a role in offering protection in dietary RPO
supplemented hearts.
The reduced coronary effluent LDH levels in RPO sup-
plemented rats confirmed that RPO supplementation was
able to offer protection against ischaemia/reperfusion
injury. This supports the infarct size result, as LDH
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release from the heart is a marker of myocardial tissue
damage.
Our results also demonstrate that RPO is more effec-
tive than SFO in offering protection against myocardial
ischaemia/reperfusion injury. This may be attributed to
several possible mechanisms. One such mechanism may
be the higher antioxidant content in RPO as compared to
SFO [41,42]. The antioxidant content of RPO may offer
an explanation for the improved protection in hearts of
RPO-supplemented rats. Previous results have shown
that dietary RPO-supplementation led to increased levels
of cGMP production, accompanied by increased intracel-
lular nitric oxide levels in myocytes [4]. These authors
suggest that antioxidants present in RPO scavenged
superoxide and thus lead to the conservation of nitric
oxide. This would in turn lead to increased cGMP- and
decreased peroxynitrite production [43-45]. This
increase in cGMP and nitric oxide, accompanied by the
decreased peroxynitrite is suggested to be one of the
pathways of protection of dietary RPO-supplementation
[1,4,5].
Serbinova and co-workers (1992) and Das and co-work-
ers (2008) used the vitamin E fraction of palm oil, named
tocotrienol rich fraction (TRF) as dietary supplement or
introduced it into the perfusate of isolated perfused
hearts [46,47]. These studies showed that TRF could offer
protection against ischaemia/reperfusion injury. In the
study by Das and co-workers (2008) the protective effects
of TRF is ascribed to its ability to increase Akt phospho-
rylation. This places the Akt phosphorylation results of
this study into perspective, as we were able to confirm
that increased Akt phosphorylation takes place when
RPO is supplemented to the diet when compared to a
sunflower oil supplemented group. This is also in agree-
ment with results by Engelbrecht and co-workers (2006)
who showed that Akt is phosphorylated by dietary RPO-
supplementation. In this study, Aktser473 was shown to be
phosphorylated, while the current study demonstrates
that the Aktthr308 residue is also phosphorylated. Das et al.
(2008) suggested that it is the tocotrienol content of palm
oil that is responsible for Akt phosphorylation. This data
supports our finding that RPO, which contains high levels
of tocotrienols, could induce phosphorylation of Akt.
SFO also contains vitamin E, but predominantly tocoph-
erols [48]. We can therefore conclude from our studies
that tocotrienols were responsible for Akt phosphoryla-
tion.
Furthermore, our results confirm previous studies
which showed that RPO does not have hypercholestero-
laemic effects [49,50]. RPO has also been shown to
decrease triglycerides to a similar level as SFO. These
results demonstrate that dietary RPO-supplementation
does not have negative effects on the serum lipid profile
normally associated with saturated fats.
Conclusion
Our results demonstrate that dietary RPO-supplementa-
tion reduces myocardial infarct size when compared to
SRC fed controls. We were also able to demonstrate that
RPO supplementation is more effective in reducing myo-
cardial infarct size than SFO fed group. MMP2 seems to
have played at most, a minor role in the reduction of
myocardial infarct size in this study, as its activity was
reduced in both the RPO- and SFO-supplemented
groups. The effects of reduced MMP2 activity may how-
ever contribute to RPO mediated protection against
ischaemia/reperfusion by working synergistically with
other mechanisms, as suggested by Van Rooyen and co-
workers (2008). Our results confirm that Akt phosphory-
lation and possibly antioxidant activity of RPO may have
been more effective in the protection offered by RPO
against ischaemia/reperfusion injury.
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